None listed
Conditions
Brief summary
This study aims to determine the impact of coeliac plexus neurolysis on pain and quality of life in patients with pancreatic cancer. Who is it for? You may be eligible to join this study if you are aged 18 years and older and have confirmed clinical diagnosis of pancreatic cancer and have cancer-related pain. Study details All participants in this study will undergo Endoscopic ultrasound (EUS) - coeliac plexus neurolysis (CPN) procedure performed by an interventional gastroenterologist. EUS-CPN is conducted as a day-only procedure under deep intravenous sedation. Participants will then be followed-up and assessed regularly for 6 months to determine the impact of EUS-CPN on pain and quality of life. Longer follow-up to 12 months post EUS-CPN procedure will be conducted to assess safety and survivorship. It is hoped that this research project will improve the quality of life of patients with pancreatic cancer through reducing pain and assisting with other activities of daily life that maybe affected by the cancer.
Interventions
Endoscopic ultrasound (EUS) - coeliac plexus neurolysis (CPN) is an endoscopic procedure performed by interventional gastroenterologists. CPN is achieved by the injection of a neurolytic agent into the CP or specific coeliac ganglia causing neurolysis or destruction of the CP or ganglia. The neurolytic agent is either pure alcohol or 10% phenol. The procedure takes 20-30minutes. It is a single procedure. Either induces a local inflammatory reaction followed by fibrosis during the healing proces
Endoscopic ultrasound (EUS) - coeliac plexus neurolysis (CPN) is an endoscopic procedure performed by interventional gastroenterologists. CPN is achieved by the injection of a neurolytic agent into the CP or specific coeliac ganglia causing neurolysis or destruction of the CP or ganglia. The neurolytic agent is either pure alcohol or 10% phenol. The procedure takes 20-30minutes. It is a single procedure. Either induces a local inflammatory reaction followed by fibrosis during the healing process. EUS-CPN is conducted as a day-only procedure under deep intravenous sedation. Recovery is swift and patients are discharged home the same day. This is not a new or complex procedure. Patients may have access to the procedure routinely if their treating clinician refers them to have this procedure. Historically, clinicians have not referred patients for the procedure due to a lengthy time to access the procedure logistically. This study seeks to validate utility of the procedure to be able to set up proper processes so patients may access it faster and the hospital provide a more efficient service. Research findings will assist uptake of evidence into this process.
Sponsors
Royal Brisbane & Women's Hospital
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
• All patients with a confirmed clinical diagnosis of pancreatic cancer • Medical documentation and treatment of abdominal pain as established by need for regular opiate use • 18 years and over
Exclusion criteria
• Advanced disease state that is impacting on capacity to consent • Patients who have painless PC not requiring regular opiate medication to treat pain, • Elevated INR > 1.5 • Decompensated cardiac failure (NYHA class IV) • Decompensated liver failure (Child-Pugh score B/C) • Severe hypotension (sBP<85mmHg) • Currently pregnant
Outcome results
None listed